Biocerta Precision Diagnostics is a functional precision oncology company transforming cancer care from trial-and-error to individualized therapy selection. Its ex vivo drug sensitivity testing platform evaluates fresh tumor tissue against more than 200 FDA-approved compounds within 14 days, uniquely comparing cancer and normal tissue responses to identify therapies that maximize efficacy while minimizing toxicity. Biocerta’s mission: Right treatment, first time, every time.

Regulatory Disclaimer:
The Biocerta Drug Sensitivity Testing (DST) platform is an investigational device. Federal law restricts this device to investigational use only. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not available for routine clinical use or commercial distribution. Access is limited to approved clinical research protocols at participating institutions. The safety and effectiveness of this device for cancer treatment selection have not been established.

Test results should not be used as the sole basis for medical decisions. This device has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. For information about clinical trial opportunities or research participation, please contact us.

Biocerta Precision Diagnostics, Inc.

Org chart

Teams

Offices